Evidence map›Paper›PMID 37773087›Full record

ArticleScientific reports2023

Renoprotective potential of concomittant medications with SGLT2 inhibitors and renin-angiotensin system inhibitors in diabetic nephropathy without albuminuria: a retrospective cohort study.

Tatsuya Ishibashi, Shuhei Morita, Hiroto Furuta, Masahiro Nishi, Taka-Aki Matsuoka

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tatsuya IshibashiFirst Department of Medicine, Wakayama Medical University, 811‑1 Kimi‑idera, Wakayama City, Wakayama, 641‑8509, Japan. t1484@wakayama-med.ac.jp.
Shuhei MoritaFirst Department of Medicine, Wakayama Medical University, 811‑1 Kimi‑idera, Wakayama City, Wakayama, 641‑8509, Japan.
Hiroto FurutaFirst Department of Medicine, Wakayama Medical University, 811‑1 Kimi‑idera, Wakayama City, Wakayama, 641‑8509, Japan.
Masahiro NishiDepartment of Medical Technology, Faculty of Health Sciences, Kansai University of Health Sciences, Sennan, Osaka, Japan.
Taka-Aki MatsuokaFirst Department of Medicine, Wakayama Medical University, 811‑1 Kimi‑idera, Wakayama City, Wakayama, 641‑8509, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The renal protective effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors and renin-angiotensin system (RAS) inhibitors on diabetic nephropathy without albuminuria have not been fully investigated. This retrospective cohort study focused on patients with type 2 diabetes mellitus who had a baseline estimated glomerular filtration rate (eGFR) of > 30 mL/min/1.73 m

Indexed as

Diabetes Mellitus, Type 2Diabetic NephropathiesSodium-Glucose Transporter 2 InhibitorsAlbuminuriaAntihypertensive AgentsEnzyme InhibitorsGlomerular Filtration RateHumansRenin-Angiotensin SystemRetrospective StudiesAntihypertensive AgentsEnzyme InhibitorsSodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID37773087
PMCPMC10541410

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.